Zobrazeno 1 - 10 of 103 pro vyhledávání: '"Tsai LF"'
1
Akademický článek
Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
Autor: De Hert M, Eramo A, Landsberg W, Kostic D, Tsai LF, Baker RA
Publikováno v: Neuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1299-1306 (2015)
Marc De Hert,1 Anna Eramo,2 Wally Landsberg,3 Dusan Kostic,4 Lan-Feng Tsai,5 Ross A Baker4 1Department of Neurosciences, KU Leuven, Belgium; 2Lundbeck LLC, Deerfield, IL, USA; 3Otsuka Pharmaceutical Europe Ltd., Wexham, UK; 4Otsuka Pharmaceutical Dev
Externí odkaz: https://doaj.org/article/7df5b485319d405f9626c74dc9091453
Zobrazit plný text záznamu
2
Akademický článek
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Autor: Ruff CT; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.T.R., J.F.K., S.A.M., M.S.S.)., Koren MJ; Jacksonville Center for Clinical Research, FL (M.J.K.)., Grimsby J; Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism (J.G., S.K.K.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology (A.I.R., Y.G.), Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA., Tu X; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (X.T., J.F., B.H., R.T.G.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Karathanasis SK; Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism (J.G., S.K.K.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Falloon J; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (X.T., J.F., B.H., R.T.G.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Hsia J; Research and Early Development, Cardiovascular, Renal and Metabolism (J.H.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Guan Y; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology (A.I.R., Y.G.), Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA., Conway J; Bioinformatics, Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Gaithersburg, MD (J.C.)., Tsai LF; Early CVRM Biometrics, Research and Early Development, Cardiovascular, Renal and Metabolism (L.-F.T.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Hummer BT; Cardiovascular, Renal and Metabolism Safety (B.T.H.), Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA., Hirshberg B; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (X.T., J.F., B.H., R.T.G.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Kuder JF; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.T.R., J.F.K., S.A.M., M.S.S.)., Murphy SA; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.T.R., J.F.K., S.A.M., M.S.S.)., George RT; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (X.T., J.F., B.H., R.T.G.), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD., Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.T.R., J.F.K., S.A.M., M.S.S.).
Publikováno v: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2021 Dec; Vol. 41 (12), pp. 3005-3014. Date of Electronic Publication: 2021 Oct 28.
Zobrazit plný text záznamu
3
Akademický článek
Visible light photocatalytic properties of one-step SnO 2 -templated grown SnO 2 /SnS 2 heterostructure and SnS 2 nanoflakes.
Autor: Wang CY; Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan., Wu YK; Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan., Tsai LF; Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan., Lee HK; Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan., Hsu YC; Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan.
Publikováno v: Nanotechnology [Nanotechnology] 2021 May 05; Vol. 32 (30). Date of Electronic Publication: 2021 May 05.
Zobrazit plný text záznamu
4
Akademický článek
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial.
Autor: Le Lay JE; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Du Q; Biologic Therapeutics, Antibody Discovery and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Mehta MB; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Bhagroo N; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Hummer BT; CVRM Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Falloon J; Clinical Development, Research and Early Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA., Carlson G; Clinical CV, Late Stage Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA., Jin C; Clinical Immunology and Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA., Kimko H; Clinical Pharmacology and DMPK, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Tsai LF; CVRM Biometrics, Data Sciences and AI, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Novick S; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Cook B; Clinical Development, Research and Early Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA., Han D; Parexel International, Glendale, CA 91206, USA., Han CY; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98915, USA., Vaisar T; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98915, USA., Chait A; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98915, USA., Karathanasis SK; Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Rhodes CJ; Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Hirshberg B; Clinical Development, Research and Early Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA., Damschroder MM; Biologic Therapeutics, Antibody Discovery and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Hsia J; Clinical Development, Research and Early Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA., Grimsby JS; Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA. joseph.grimsby@astrazeneca.com.
Publikováno v: Science translational medicine [Sci Transl Med] 2021 Apr 21; Vol. 13 (590).
Zobrazit plný text záznamu
5
Akademický článek
High-stability inorganic perovskite quantum dot-cellulose nanocrystal hybrid films.
Autor: Chiang CH; Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan., Li TY, Wu HS, Li KY, Hsu CF, Tsai LF, Yang PK, Lee YJ, Lee HC, Wang CY, Tsai ML
Publikováno v: Nanotechnology [Nanotechnology] 2020 Aug 07; Vol. 31 (32), pp. 324002. Date of Electronic Publication: 2020 May 26.
Zobrazit plný text záznamu
6
Akademický článek
ABO genotyping with next-generation sequencing to resolve heterogeneity in donors with serology discrepancies.
Autor: Wu PC; Taipei Blood Center, Taiwan Blood Services Foundation, National Taiwan University Hospital, Taipei, Taiwan., Lin YH; Graduate Institute of Medical Genomics and Proteomics, National Taiwan University Hospital, Taipei, Taiwan., Tsai LF; Taipei Blood Center, Taiwan Blood Services Foundation, National Taiwan University Hospital, Taipei, Taiwan., Chen MH; Taipei Blood Center, Taiwan Blood Services Foundation, National Taiwan University Hospital, Taipei, Taiwan., Chen PL; Graduate Institute of Medical Genomics and Proteomics, National Taiwan University Hospital, Taipei, Taiwan.; Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan., Pai SC; Taipei Blood Center, Taiwan Blood Services Foundation, National Taiwan University Hospital, Taipei, Taiwan.
Publikováno v: Transfusion [Transfusion] 2018 Sep; Vol. 58 (9), pp. 2232-2242. Date of Electronic Publication: 2018 May 16.
Zobrazit plný text záznamu
7
Akademický článek
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Autor: Ambery P; Cardiovascular, Renal, and Metabolism, MedImmune, Cambridge, UK. Electronic address: amberyp@medImmune.com., Parker VE; Cardiovascular, Renal, and Metabolism, MedImmune, Cambridge, UK., Stumvoll M; University Hospital Leipzig, Leipzig, Germany., Posch MG; Charité Research Organisation GmbH, Berlin, Germany., Heise T; Profil, Neuss, Germany., Plum-Moerschel L; Profil, Mainz, Germany., Tsai LF; MedImmune, Gaithersburg, MD, USA., Robertson D; Cardiovascular, Renal, and Metabolism, MedImmune, Cambridge, UK., Jain M; Cardiovascular, Renal, and Metabolism, MedImmune, Cambridge, UK., Petrone M; Cardiovascular, Renal, and Metabolism, MedImmune, Cambridge, UK., Rondinone C; MedImmune, Gaithersburg, MD, USA., Hirshberg B; MedImmune, Gaithersburg, MD, USA., Jermutus L; Cardiovascular, Renal, and Metabolism, MedImmune, Cambridge, UK.
Publikováno v: Lancet (London, England) [Lancet] 2018 Jun 30; Vol. 391 (10140), pp. 2607-2618. Date of Electronic Publication: 2018 Jun 23.
Zobrazit plný text záznamu
8
Akademický článek
Equity in blood transfusion precision services.
Autor: Jacko, Georgina1 gjacko@redcrossblood.org.au, Thorpe, Rachel2,3, Daly, James1
Publikováno v: International Journal for Equity in Health. 4/18/2024, Vol. 23 Issue 1, p1-6. 6p.
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje